Octavio Espinoza - 30 Dec 2022 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role
Chief Financial Officer
Signature
/s/ Andrew Reardon, Attorney-in-Fact for Octavio Espinoza
Issuer symbol
LGND
Transactions as of
30 Dec 2022
Net transactions value
+$15,614
Form type
4
Filing time
04 Jan 2023, 16:00:15 UTC
Previous filing
27 Dec 2022
Next filing
17 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LGND Common Stock Other $15,614 +275 +1.5% $56.78 18,945 30 Dec 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares acquired under Ligand's employee stock purchase plan. Voluntary reporting exemption under Rule 16b-3(c).